ライフサイエンスコーパス: mesenchymal stromal cell

1 surround a single HSPC attached to a single mesenchymal stromal cell.

2 by Mcl-1 or by interactions with bone marrow mesenchymal stromal cells.

3 h the recipient's respiratory epithelium and mesenchymal stromal cells.

4 y in promoting osteogenic differentiation of mesenchymal stromal cells.

5 duces collagen deposition in the bone marrow mesenchymal stromal cells.

6 ose-derived stromal cells and marrow-derived mesenchymal stromal cells.

7 d defects in skull, articular cartilage, and mesenchymal stromal cells.

8 expressed in cells and tissues arising from mesenchymal stromal cells.

9 ng cord blood that was expanded ex vivo with mesenchymal stromal cells.

10 panded ex vivo in cocultures with allogeneic mesenchymal stromal cells.

11 l progenitor colony cells were surrounded by mesenchymal stromal cells.

12 through donor-derived mononuclear cells and mesenchymal stromal cells.

13 es, and an immunophenotype characteristic of mesenchymal stromal cells.

14 further improve the therapeutic potential of mesenchymal stromal cells.

15 sing the patient's own immune or bone marrow mesenchymal stromal cells.

16 A, which expressed surface markers common to mesenchymal stromal cells.

17 Endomyocardial injections of iron-labeled mesenchymal stromal cells admixed with tissue dye were p

18 sibility of using autologous adipose-derived mesenchymal stromal cells (AdMSCs) for the treatment of

19 Adipose tissue contains adipose-derived mesenchymal stromal cells (ADSCs) that have regenerative

20 agen VII expressed by intradermally injected mesenchymal stromal cells also exhibited a similar half-

21 Live imaging showed that mesenchymal stromal cells anchor HSPCs and orient their

22 erse relationship between a subpopulation of mesenchymal stromal cells and cancer cells in the bone m

23 ation inhibits the regenerative potential of mesenchymal stromal cells and derived extracellular vesi

24 Whereas wild-type mesenchymal stromal cells and derived vesicles administe

25 after injury were restored by treatment with mesenchymal stromal cells and derived vesicles but not w

26 gineered by inducing chondrogenesis of human mesenchymal stromal cells and devitalized by the impleme

27 The niche is perivascular, created partly by mesenchymal stromal cells and endothelial cells and ofte

28 ramedullary bone and bone marrow using human mesenchymal stromal cells and endothelial colony-forming

29 rm repopulating of hematopoietic stem cells, mesenchymal stromal cells and endothelial progenitors.

30 ions reverted after treatment with wild-type mesenchymal stromal cells and extracellular vesicles but

31 In conclusion, microRNA depletion in mesenchymal stromal cells and extracellular vesicles sig

32 Mesenchymal stromal cells and liver fibrosis: a complica

33 The CD40/CD40L-assisted crosstalk between mesenchymal stromal cells and mast cells populating the

34 ne marrow myofibroblasts derive from Gli1(+) mesenchymal stromal cells and that a Gli inhibitor targe

35 t nonmalignant peripheral blood lymphocytes, mesenchymal stromal cells, and CD34-positive hematopoiet

36 signalling, adhesion to primary bone-marrow mesenchymal stromal cells, and proliferation of primary

37 plantation of cord-blood cells expanded with mesenchymal stromal cells appeared to be safe and effect

38 Mesenchymal stromal cells are being investigated as a ce

39 nvestigate the paracrine mechanisms by which mesenchymal stromal cells are protective in hypoxic pulm

40 re the safety, tolerability, and efficacy of mesenchymal stromal cell-based therapy in pilot clinical

41 In vitro studies have shown that bone marrow mesenchymal stromal cells (BM-MSC) protect AML blasts fr

42 Bone marrow-derived mesenchymal stromal cells (BM-MSCs) in culture are deriv

43 BM mesenchymal stromal cells (BM-MSCs) support multiple mye

44 ve this challenge, human bone marrow-derived mesenchymal stromal cells (BM-MSCs) were used to efficie

45 tosis by their interactions with bone marrow mesenchymal stromal cells (BM-MSCs).

46 comparable to osteogenic cells derived from mesenchymal stromal cells (BM-MSCs).

47 stem cells (iHepSCs) and bone marrow derived mesenchymal stromal cells (BMSCs) were used to CBTs for

48 in a loss of therapeutic benefit bestowed on mesenchymal stromal cells by carbon monoxide.

49 -inducible factor 1alpha was knocked down in mesenchymal stromal cells by lentiviral transfer of shor

50 ave shown convincingly in rodent models that mesenchymal stromal cells can prolong solid organ graft

51 te+/-SE, 0.01+/-0.002; P<0.001), multipotent mesenchymal stromal cell colony maximum (estimate+/-SE,

52 mate+/-SE, 0.01+/-0.002; P=0.002) in BM, and mesenchymal stromal cell colony maximum in PB (estimate+

53 We fractionated mouse mesenchymal stromal cell-conditioned media to identify t

54 Mesenchymal stromal cells, mesenchymal stromal cells-conditioned with carbon monoxi

55 n in BM stromal elements, including CD146(+) mesenchymal stromal cells, correlates with the degree of

56 We showed that mesenchymal stromal cells, cortical bone stem cells, and

57 Mesenchymal stromal cells create and maintain specialize

58 We generated mesenchymal stromal cells depleted of Drosha to alter mi

59 Intravenous delivery of mesenchymal stromal cell-derived exosomes (MEX) inhibite

60 lving lipid mediators contribute to improved mesenchymal stromal cell efficacy when exposed to carbon

61 in situ differentiation of human BM-derived mesenchymal stromal cells, enables the robust engraftmen

62 in vivo selection of cytokines that improve mesenchymal stromal cell engraftment into the heart both

63 he batch transduction of bone marrow-derived mesenchymal stromal cells ex vivo, followed by intramyoc

64 Mesenchymal stromal cells exposed to carbon monoxide, wi

65 separation efficacy of >98% in pre-purified mesenchymal stromal cells, extracted from human dental p

66 Bone marrow-derived mesenchymal stromal cells from hypomorphic mice, as well

67 Multipotent mesenchymal stromal cells from the bone marrow ameliorat

68 ng lipid mediators, and their importance for mesenchymal stromal cells function using gene silencing.

69 modulatory efficacy of regulatory T cells or mesenchymal stromal cells has been demonstrated in vitro

70 The differentiation of mesenchymal stromal cells has been shown to be affected

71 Mesenchymal stromal cells have emerged as potential cand

72 Mesenchymal stromal cells have emerged as powerful modul

73 Human multipotent mesenchymal stromal cells (hMSCs) produce tumor necrosis

74 Scaffolds coated with human mesenchymal stromal cells (hMSCs) proved to be superior

75 Human mesenchymal stromal cells (hMSCs) were injected into the

76 ation of bone forming osteoblasts from human mesenchymal stromal cells (hMSCs).

77 acts directly on Leptin-Receptor-expressing mesenchymal stromal cells in adult bone marrow to influe

78 s significantly augmented in macrophages and mesenchymal stromal cells in inflamed human pulp tissues

79 and osteogenic activity, a critical role for mesenchymal stromal cells in osteogenesis, and temporal

80 g regulates adipogenesis and osteogenesis by mesenchymal stromal cells in the bone marrow in response

81 ation toward CXCL12 and reducing adhesion to mesenchymal stromal cells in vitro We also found that HI

82 of mesenchymal stem cells (MSCs, also called mesenchymal stromal cells) in endogenous repair and cell

83 ing Dab2-deficient embryonic fibroblasts and mesenchymal stromal cells indicated that Dab2 promoted a

84 MEX produced by human umbilical cord mesenchymal stromal cells inhibited STAT3 signaling in i

85 planting ceramic scaffolds coated with human mesenchymal stromal cells into immune-deficient mice, we

86 brain injured mice receiving human amniotic mesenchymal stromal cells intravenously or intracerebrov

87 Coculture with mesenchymal stromal cells led to an expansion of total n

88 In addition, mesenchymal stromal cells may participate in several ste

89 Mesenchymal stromal cells, mesenchymal stromal cells-con

90 ion were assessed in bone marrow multipotent mesenchymal stromal cell models.

91 about the potentially unfavorable effects of mesenchymal stromal cell (MSC) activation on the heart.

92 Advances in the field of Multipotent Mesenchymal Stromal cell (MSC) biology have demonstrated

93 stretch have been investigated for inducing mesenchymal stromal cell (MSC) differentiation towards t

94 Human mesenchymal stromal cell (MSC) lines can vary significan

95 But the mechanisms underlying OA-mediated mesenchymal stromal cell (MSC) osteogenic differentiatio

96 to isolate a quiescent and undifferentiated mesenchymal stromal cell (MSC) population from the bone

97 Original techniques based on mesenchymal stromal cell (MSC) therapy are emerging with

98 Mesenchymal stromal cell (MSC) therapy demands the atten

99 Clinical trials investigating mesenchymal stromal cell (MSC) therapy for bronchopulmon

100 Autologous mesenchymal stromal cell (MSC) treatments have shown fea

101 ll apoptosis, and could overcome bone marrow mesenchymal stromal cell (MSC)-induced chemoresistance.

102 ion (DR) in both ex vivo bone marrow-derived mesenchymal stromal cells (MSC) and in vitro 3T3-L1 prea

103 Mesenchymal stromal cells (MSC) are potential renal ther

104 Mesenchymal stromal cells (MSC) are used extensively in

105 The ability to use mesenchymal stromal cells (MSC) directly out of cryostor

106 contributions to primary myelofibrosis from mesenchymal stromal cells (MSC) have been suggested by m

107 premetastatic niche by examining the role of mesenchymal stromal cells (MSC) in cancer cell homing.

108 ure of leukemia cells to bone marrow-derived mesenchymal stromal cells (MSC) promotes accumulation of

109 posure of cultured mouse bone marrow-derived mesenchymal stromal cells (MSC) to hypoxia or an adenovi

110 Autologous mesenchymal stromal cells (MSC) treatments have shown fe

111 (CAF) have been suggested to originate from mesenchymal stromal cells (MSC), but their relationship

112 ytic leukemic (CLL) cells and marrow-derived mesenchymal stromal cells (MSCs) activates both cell typ

113 These enzymes were detected both in LN mesenchymal stromal cells (MSCs) and in Reed-Sternberg (

114 Adherent progenitor cells, including mesenchymal stromal cells (MSCs) and multipotent adult p

115 Mesenchymal stromal cells (MSCs) are a major component o

116 Mesenchymal stromal cells (MSCs) are a promising candida

117 vironments that modulate fate commitments of mesenchymal stromal cells (MSCs) are composed of chemica

118 As mesenchymal stromal cells (MSCs) are continuously expose

119 Multipotent mesenchymal stromal cells (MSCs) are found in an increas

120 Mesenchymal stromal cells (MSCs) are heterogeneous and p

121 Mesenchymal stromal cells (MSCs) are immunomodulatory an

122 Nestin-expressing (Nestin(+)) mesenchymal stromal cells (MSCs) are important in the pe

123 Mesenchymal stromal cells (MSCs) are inherently tumor ho

124 Mesenchymal stromal cells (MSCs) are multipotent cells w

125 Mesenchymal stromal cells (MSCs) are one of major compon

126 RATIONALE: Mesenchymal stromal cells (MSCs) are promising therapeut

127 Multipotent mesenchymal stromal cells (MSCs) are rare cells resident

128 ing in two murine models of BMF that Gli1(+) mesenchymal stromal cells (MSCs) are recruited from the

129 Mesenchymal stromal cells (MSCs) are strongly immunosupp

130 Mesenchymal stromal cells (MSCs) constitute, based on an

131 ed with long-term passaged (P10) aging human mesenchymal stromal cells (MSCs) could be used for bone

132 y demonstrated that coculture of islets with mesenchymal stromal cells (MSCs) enhanced islet insulin

133 ) cells in the presence of bone marrow-human mesenchymal stromal cells (MSCs) enhanced the production

134 in preparation for a first-in-human trial of mesenchymal stromal cells (MSCs) for septic shock, we ap

135 n a rapid expansion in clinical trials using mesenchymal stromal cells (MSCs) from a variety of tissu

136 d the adipogenic potential of marrow-derived mesenchymal stromal cells (MSCs) from mice with decrease

137 the BM extracellular fluid were elevated and mesenchymal stromal cells (MSCs) had a reduced capacity

138 Use of mesenchymal stromal cells (MSCs) has become standard pra

139 f the identity and physiological function of mesenchymal stromal cells (MSCs) have been hampered by a

140 Mesenchymal stromal cells (MSCs) have enormous potential

141 Mesenchymal stromal cells (MSCs) have great potential to

142 Mesenchymal stromal cells (MSCs) have immune modulatory

143 Mesenchymal stromal cells (MSCs) have the potential to t

144 and safety of osteoarthritis treatment with mesenchymal stromal cells (MSCs) in humans and to obtain

145 strate expression exclusively in multipotent mesenchymal stromal cells (MSCs) in the bone marrow of t

146 eviously identified a resident population of mesenchymal stromal cells (MSCs) in the terminal airways

147 ctor [SCF], ThPO, and IL-6) from bone marrow mesenchymal stromal cells (MSCs) in vitro.

148 Human bone marrow-derived mesenchymal stromal cells (MSCs) inhibit proliferation o

149 steering the chondrogenic differentiation of mesenchymal stromal cells (MSCs) into either permanent c

150 val, growth, and myogenic differentiation of mesenchymal stromal cells (MSCs) isolated from adipose o

151 one marrow (BMT) as well as ex vivo-expanded mesenchymal stromal cells (MSCs) leads to striking clini

152 the hypothesis that the favorable effects of mesenchymal stromal cells (MSCs) on infarct repair are m

153 ated when the CLL cells were cocultured with mesenchymal stromal cells (MSCs) or hyaluronic acid or w

154 Multipotent mesenchymal stromal cells (MSCs) possess reparative and

155 Mesenchymal stromal cells (MSCs) present in the bone mar

156 Topically applied mesenchymal stromal cells (MSCs) provide a novel treatme

157 Coculture with human BM mesenchymal stromal cells (MSCs) significantly inhibited

158 In addition, mesenchymal stromal cells (MSCs) support in vitro FL B-c

159 Mesenchymal stromal cells (MSCs) tend to infiltrate into

160 Activated T cells polarize mesenchymal stromal cells (MSCs) to a proinflammatory Th

161 local administration of bone marrow-derived mesenchymal stromal cells (MSCs) to these patients from

162 eutically relevant quantities of multipotent mesenchymal stromal cells (MSCs) via in vitro culture is

163 luid (SF) in the knee serve as reservoirs of mesenchymal stromal cells (MSCs) with potential therapeu

164 CSF) secreted from human bone marrow-derived mesenchymal stromal cells (MSCs), all of which also cont

165 one marrow (BM) affects local cells, such as mesenchymal stromal cells (MSCs), leading to osteolysis

166 emia (CLL) cells interact in the marrow with mesenchymal stromal cells (MSCs), which can enhance CLL-

167 ociated cells, including dendritic cells and mesenchymal stromal cells (MSCs).

168 ngiogenic and immunomodulatory properties to mesenchymal stromal cells (MSCs).

169 to as mesenchymal stem cells or multipotent mesenchymal stromal cells (MSCs).

170 med by in situ differentiation of BM-derived mesenchymal stromal cells (MSCs).

171 three-dimensional (3D) condensates of human mesenchymal stromal cells (MSCs).

172 BCP-ALL) cells use TNTs to signal to primary mesenchymal stromal cells (MSCs).

173 Although multipotent mesenchymal stromal cells (MSCs, also termed 'mesenchyma

174 deprivation and treated with human amniotic mesenchymal stromal cells or conditioned medium showed c

175 lled cortical impact received human amniotic mesenchymal stromal cells or phosphate-buffered saline i

176 deprivation were treated with human amniotic mesenchymal stromal cells or with their secretome (condi

177 ndent phenotypic changes of nonhematopoietic/mesenchymal stromal cells play a key role in TD humoral

178 Upon i.v. injection of bone marrow mesenchymal stromal cells, postischemic functional renal

179 tracellular vesicles have been implicated in mesenchymal stromal cell-promoted recovery of AKI.

180 originate from BM, or of healthy BM-derived mesenchymal stromal cells, protected hemophilia A mice f

181 Human amniotic mesenchymal stromal cell-secreted factors protect the br

182 Seeded allogeneic mesenchymal stromal cells spontaneously differentiate (p

183 arrow (BM) fibrosis thought to be induced by mesenchymal stromal cells stimulated by overproduced gro

184 rved between the amount of FSTL1 produced by mesenchymal stromal cells, stromal ST2 cells, and monocy

185 eview the available data on culture-expanded mesenchymal stromal cells tested in renal transplantatio

186 In this study, we investigate whether mesenchymal stromal cells that constitute a supportive m

187 ous assessment of the safety and efficacy of mesenchymal stromal cell therapies to allow the translat

188 have produced promising results for HSCT and mesenchymal stromal cell therapy as alternatives to syst

189 For patients with fistulizing CD, mesenchymal stromal cell therapy deposits MSCs locally,

190 poietic stem cell transplantation (HSCT) and mesenchymal stromal cell therapy have been proposed for

191 Early clinical trials of mesenchymal stromal cell therapy have shown promising re

192 skin, and suggest an approach for improving mesenchymal stromal cell therapy in scleroderma and othe

193 preconditioning with carbon monoxide allowed mesenchymal stromal cells to be administered later after

194 e osteoblast precursor cells and rat primary mesenchymal stromal cells to low-dose PDT.

195 dicating that the exposure of human amniotic mesenchymal stromal cells to the injured tissue is not n

196 Intracardiac injection of mesenchymal stromal cells transiently preconditioned wit

197 Mesenchymal stromal cell transplantation inhibits lung i

198 Engraftment of cardiotrophin-1-treated mesenchymal stromal cells was consequent to signal trans

199 Carbon monoxide preconditioned mesenchymal stromal cells were also able to alleviate or

200 Mesenchymal stromal cells were also assessed for their a

201 y contrast, donor BM-derived mononuclear and mesenchymal stromal cells were more abundant and express

202 roinflammatory cytokines in BM-derived human mesenchymal stromal cells, which are part of the hematop

203 We hypothesized that preconditioning of mesenchymal stromal cells with carbon monoxide ex vivo w

204 We conclude that harnessing local mesenchymal stromal cells with FGF9 can differentiate th

205 , and activation of EphA3(+)/CD90(+)/Sca1(+) mesenchymal/stromal cells with an EphA3 agonist leads to